2015
DOI: 10.2217/nnm.15.47
|View full text |Cite
|
Sign up to set email alerts
|

Nanocarriers for Treatment of Ocular Neovascularization in the Back of the Eye: New Vehicles for Ophthalmic Drug Delivery

Abstract: Pathologic neovascularization of the retina is a major cause of substantial and irreversible loss of vision. Drugs are difficult to deliver to the lesions in the back of the eye and this is a major obstacle for the therapeutics. Current pharmacological approach involves an intravitreal injection of anti-VEGF agents to prevent aberrant growth of blood vessels, but it has limitations including therapeutic efficacy and side-effects associated with systemic exposure and invasive surgery. Nanotechnology provides no… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
29
0
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 49 publications
(30 citation statements)
references
References 84 publications
0
29
0
1
Order By: Relevance
“…Even though intravitreal injections are generally safe, the monthly and bimonthly requirements for these injections in long-term treatment may cause problems such as infection and reduced patient compliance [128][129][130][131][132]. For these reasons, intravitreal drug delivery systems are needed that will maintain therapeutic drug concentrations for an extended time, prolong the drug effect, and reduce the required number of applications [128,130,131,[133][134][135]. Obviously, the systems must also be safe and ideally they must be biodegradable, as biodegradable drug delivery systems do not require subsequent surgery to remove them from the eye [133].…”
Section: Intravitreal Administrationmentioning
confidence: 99%
“…Even though intravitreal injections are generally safe, the monthly and bimonthly requirements for these injections in long-term treatment may cause problems such as infection and reduced patient compliance [128][129][130][131][132]. For these reasons, intravitreal drug delivery systems are needed that will maintain therapeutic drug concentrations for an extended time, prolong the drug effect, and reduce the required number of applications [128,130,131,[133][134][135]. Obviously, the systems must also be safe and ideally they must be biodegradable, as biodegradable drug delivery systems do not require subsequent surgery to remove them from the eye [133].…”
Section: Intravitreal Administrationmentioning
confidence: 99%
“…This emphasizes the need for in-depth studies regarding the delivery method 115,116 and the need/efficacy of gene manipulation of MSCs prior to treatment.…”
Section: Therapeutic Potential Of Mesenchymal Stem Cellsmentioning
confidence: 99%
“…Because continuing oxidative stress damages the retina over time and activation of Nrf2 is not expected to reverse cellular death, preventing the progress of dry AMD might be a more promising target, as in the case of the AREDS study. Systemic adverse events are still a big concern of triterpenoids; therefore, administering them via eye drops or intraocular implants would be a promising approach for lowering these risks [55, 56]. …”
Section: Nrf2 Activators Ameliorate Oxidative Stress-related Retinmentioning
confidence: 99%